Kymera Therapeutics (NASDAQ:KYMR) Earns Buy Rating from Analysts at Citigroup

Citigroup started coverage on shares of Kymera Therapeutics (NASDAQ:KYMR - Free Report) in a research note published on Thursday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $52.00 price target on the stock.

KYMR has been the subject of a number of other reports. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $38.00 to $57.00 in a report on Monday, December 2nd. BTIG Research started coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They set a "buy" rating and a $60.00 price target for the company. BMO Capital Markets started coverage on shares of Kymera Therapeutics in a report on Friday, December 6th. They set a "market perform" rating and a $55.00 price target for the company. Leerink Partners restated an "outperform" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Finally, HC Wainwright upped their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Kymera Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $56.36.

Remove Ads

Kymera Therapeutics Stock Up 0.3 %

Shares of Kymera Therapeutics stock traded up $0.12 during trading on Thursday, reaching $34.49. The company's stock had a trading volume of 374,478 shares, compared to its average volume of 519,803. The firm's 50-day moving average is $37.43 and its two-hundred day moving average is $42.76. Kymera Therapeutics has a 52-week low of $29.07 and a 52-week high of $53.27. The company has a market cap of $2.24 billion, a price-to-earnings ratio of -14.74 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. On average, equities research analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Activity at Kymera Therapeutics

In related news, insider Ellen Chiniara sold 2,241 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the sale, the insider now directly owns 80,085 shares of the company's stock, valued at approximately $2,438,588.25. This represents a 2.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the sale, the chief operating officer now directly owns 67,800 shares in the company, valued at approximately $2,064,510. The trade was a 2.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 13,788 shares of company stock valued at $455,202. 15.82% of the stock is owned by insiders.

Institutional Trading of Kymera Therapeutics

Institutional investors have recently made changes to their positions in the stock. Blue Trust Inc. boosted its holdings in shares of Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after acquiring an additional 270 shares during the last quarter. State of Wyoming purchased a new stake in shares of Kymera Therapeutics during the 4th quarter valued at about $45,000. GF Fund Management CO. LTD. purchased a new stake in shares of Kymera Therapeutics during the 4th quarter valued at about $55,000. Quarry LP purchased a new stake in shares of Kymera Therapeutics during the 3rd quarter valued at about $95,000. Finally, KBC Group NV boosted its holdings in shares of Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after acquiring an additional 752 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.